

Company Registration No. 07214101 (England and Wales)

PATHOLOGY OXFORD LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2019
PAGES FOR FILING WITH REGISTRAR

PATHOLOGY OXFORD LIMITED

CONTENTS

	Page
Balance sheet	1
Statement of changes in equity	2
Notes to the financial statements	3 - 6

PATHOLOGY OXFORD LIMITED

BALANCE SHEET

AS AT 30 APRIL 2019

	Notes	2019 £	£	2018 £	£
Tangible assets	4		-		-
			<u>-</u>		<u>-</u>
			-		-
Current assets					
Stocks		1,150		1,150	
Debtors	5	8,460		6,000	
Cash at bank and in hand		5,039		3,738	
		<u>14,649</u>		<u>10,888</u>	
Creditors: amounts falling due within one year	6	<u>(23,737)</u>		<u>(10,448)</u>	
Net current (liabilities)/assets			<u>(9,088)</u>		<u>440</u>
			<u><u>(9,088)</u></u>		<u><u>440</u></u>
Capital and reserves					
Called up share capital	7		100		100
Profit and loss reserves			<u>(9,188)</u>		<u>340</u>
Total equity			<u><u>(9,088)</u></u>		<u><u>440</u></u>

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.

For the financial year ended 30 April 2019 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and signed by the director and authorised for issue on 3 November 2019

Dr C Clelland
Director

Company Registration No. 07214101

PATHOLOGY OXFORD LIMITED

STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 30 APRIL 2019

	Share capital	Profit and loss reserves	Total
Notes	£	£	£
Balance at 1 May 2017	100	25,499	25,599
Year ended 30 April 2018:			
Profit and total comprehensive income for the year	-	21,441	21,441
Dividends	-	(46,600)	(46,600)
	<u>100</u>	<u>340</u>	<u>440</u>
Balance at 30 April 2018	100	340	440
Year ended 30 April 2019:			
Loss and total comprehensive income for the year	-	(9,528)	(9,528)
	<u>100</u>	<u>(9,188)</u>	<u>(9,088)</u>
Balance at 30 April 2019	<u>100</u>	<u>(9,188)</u>	<u>(9,088)</u>

PATHOLOGY OXFORD LIMITED

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2019

1 Accounting policies

Company information

Pathology Oxford Limited is a private company limited by shares incorporated in England and Wales. The registered office is 264 Banbury Road, Oxford, OX2 7DY.

1.1 Accounting convention

These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

The directors are committed to providing their continued financial support to the company for the foreseeable future and therefore these accounts have been prepared on the going concern basis.

1.3 Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes.

1.4 Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is over 5 years.

1.5 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Equipment	33% Straight Line
-----------	-------------------

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.6 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

PATHOLOGY OXFORD LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 APRIL 2019

1 Accounting policies **(Continued)**

1.7 Cash at bank and in hand

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8 Financial instruments

The company has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

1.9 Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.10 Taxation

The tax expense represents the sum of the tax currently payable.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

2 Employees

The average monthly number of persons (including directors) employed by the company during the year was 1 (2018 - 1).

3 Intangible fixed assets

	Amortisation £
Cost	
At 1 May 2018 and 30 April 2019	15,525
	<hr/>
Amortisation and impairment	
At 1 May 2018 and 30 April 2019	15,525
	<hr/>
Carrying amount	
At 30 April 2019	-
	<hr/> <hr/>
At 30 April 2018	-
	<hr/> <hr/>

PATHOLOGY OXFORD LIMITED

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 30 APRIL 2019

8 Directors' transactions

Dividends totalling £nil (2018 - £12,100) were paid in the year in respect of Ordinary A shares held by the company's director.

Dividends totalling £nil (2018 - £34,500) were paid in the year in respect of Ordinary B shares held by a non director.

At the year end the the company owed the director £20,737 (2018 - £1,627). The loan is interest free and there is no date for repayment.

Other debtors includes a loan amounting to £6,000 to Premier Health Checks Limited, a company that Dr Clelland is also a director of. The loan is unsecured and there is no date for repayment.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.